0001021408-01-508760.txt : 20011030 0001021408-01-508760.hdr.sgml : 20011030 ACCESSION NUMBER: 0001021408-01-508760 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20011025 ITEM INFORMATION: Other events FILED AS OF DATE: 20011025 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SALIX PHARMACEUTICALS LTD CENTRAL INDEX KEY: 0001009356 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943267443 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23265 FILM NUMBER: 1766430 BUSINESS ADDRESS: STREET 1: 8540 COLONNADE CENTER DR STREET 2: SUITE 501 CITY: RALEIGH STATE: NC ZIP: 27615 BUSINESS PHONE: 9198621000 MAIL ADDRESS: STREET 1: 8540 COLONNADE CENTER DR STREET 2: SUITE 501 CITY: RALEIGH STATE: NC ZIP: 27615 FORMER COMPANY: FORMER CONFORMED NAME: SALIX HOLDINGS LTD DATE OF NAME CHANGE: 19970807 8-K 1 d8k.txt FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 25, 2001 SALIX PHARMACEUTICALS, LTD. ---------------------------------------------------------- (Exact name of registrant as specified in its charter) British Virgin Islands ---------------------------------------------------------- (State or other jurisdiction of incorporation) 000-23265 94-3267443 ------------------------------------ ------------------------------------ (Commission file Number) (IRS Employer ID Number)
8540 Colonnade Center Drive, Suite 501, Raleigh, North Carolina 27615 ------------------------------------------------------------------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (919) 862-1000 --------------------------- Item 5. Other Events and Regulation FD Disclosure On October 25, 2001, Salix Pharmaceuticals announced (1) it will report third quarter 2001 financial results before the market opens on Thursday, November 1, 2001, and (2) the expansion of its gastroenterology specialty sales force. Copies of the press releases related to these events are attached as exhibits. SIGNATURES ---------- Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SALIX PHARMACEUTICALS, LTD. Date: October 25, 2001 By: /s/ Adam C. Derbyshire ------------------------ Adam C. Derbyshire Vice President and Chief Financial Officer EX-99.1 3 dex991.txt PRESS RELEASE DATED OCT. 25, 2001 EXHIBIT 99.1 FOR IMMEDIATE RELEASE Contact: Adam C. Derbyshire Mike Freeman Vice President and Director, Investor Relations and Chief Financial Officer Corporate Communications 919-862-1000 919-862-1000 SALIX PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2001 CONFERENCE CALL AND WEBCAST RALEIGH, NC, October 25, 2001 - Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) today announced that the Company will report third quarter 2001 financial results before the market opens on Thursday, November 1, 2001. The Company will host a conference call at 8:30 a.m. ET on November 1. Interested parties may access the conference call by way of webcast or telephone. The live webcast will be available at http://www.salixpharm.com. To ------------------------- access the live webcast, log on to the Company's web site at the address listed above and go to the investor information section. The webcast will be archived on the Company's web site through November 7. The telephone numbers to access the conference call are (800) 474-8920 (U.S. and Canada) or (719) 457-2727 (international.) A replay of the call will be available from 11:30 a.m. ET, November 1 through November 7. The telephone numbers to access the replay of the call are (888) 203-1112 (U.S. and Canada) or (719) 457-0820 (international.) The access code for the replay is 550071. Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix's strategy is to in-license proprietary therapeutic drugs which have an existing database of positive, late-stage clinical data; complete the development and regulatory submission of these products; and market them through the Company's gastroenterology specialty sales force. Salix's lead product is COLAZAL(TM), an anti-inflammatory drug approved for the treatment of mildly to moderately active ulcerative colitis. The Company launched the product in the U.S. through its specialty sales force in January 2001. Salix's follow-on product candidate is rifaximin, currently in development for the potential treatment of infections of the lower gastrointestinal tract. The Company currently intends to submit an NDA for rifaximin for the treatment of infectious diarrhea to the U.S. FDA in December 2001. Salix trades on the Nasdaq National Market under the ticker symbol "SLXP." For more information please contact the Company at 919-862-1000 or visit our web site at www.salixpharm.com. ------------------ ### Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include the uncertainty of market acceptance of COLAZAL and rifaximin, our limited sales and marketing experience, risks of clinical trials and regulatory review, and the need to acquire new products. The reader is referred to the documents that the Company files from time to time with the Securities and Exchange Commission. EX-99.2 4 dex992.txt PRESS RELEASE DATED OCT. 25, 2001 EXHIBIT 99.2 FOR IMMEDIATE RELEASE Contact: Adam C. Derbyshire Mike Freeman Vice President and Director, Investor Relations and Chief Financial Officer Corporate Communications 919-862-1000 919-862-1000 SALIX PHARMACEUTICALS EXPANDS SPECIALTY SALES FORCE RALEIGH, NC, October 25, 2001 - Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) today announced the expansion of its gastroenterology specialty sales force. The Company now has a team of 60 professionals - 56 field sales representatives and 4 TeleSales representatives - calling on a targeted audience of gastroenterologists and other high prescribers of products to treat ulcerative colitis. In announcing the expansion, Carolyn Logan, Senior Vice President, Sales and Marketing, commented, "The Company's inaugural sales force of 30 representatives has done an exceptional job introducing COLAZAL(TM) to physicians across the United States. Due to the efforts of our sales force, Salix is becoming recognized by gastroenterologists as a trusted and valuable partner. Every member of our sales force is an experienced and proven performer. Our sales representatives have an average of five years experience in pharmaceutical sales, with the majority of them having experience in the field of gastroenterology. Without exception, every member of the team has been recognized for award-winning performance during his or her career. "Physicians and patients continue to report an exceptionally high level of satisfaction with COLAZAL. We are taking action to build on the momentum our efforts are creating in the marketplace. A sales force of 55 to 60 representatives is needed to provide the most effective coverage of the gastroenterology market. The expansion of our sales force at this time allows Salix to better capitalize on the near-term opportunity represented by COLAZAL. Looking further out, our expanded sales team should also better position the Company to market additional products as Salix expands its portfolio." Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix's strategy is to in-license proprietary therapeutic drugs which have an existing database of positive, late-stage clinical data; complete the development and regulatory submission of these products; and market them through the Company's gastroenterology specialty sales force. Salix's lead product is COLAZAL(TM), an anti-inflammatory drug approved for the treatment of mildly to moderately active ulcerative colitis. The Company launched the product in the U.S. through its specialty sales force in January 2001. Salix's follow-on product candidate is rifaximin, currently in development for the potential treatment of infections of the lower gastrointestinal tract. The Company currently intends to submit an NDA for rifaximin for the treatment of infectious diarrhea to the U.S. FDA in December 2001. Salix trades on the Nasdaq National Market under the ticker symbol "SLXP." For more information please contact the Company at 919-862-1000 or visit our web site at www.salixpharm.com. ------------------ ### Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include our limited sales and marketing experience, management of rapid growth, the uncertainty of market acceptance of COLAZAL and rifaximin, risks of clinical trials and regulatory review, and the need to acquire additional products. The reader is referred to the documents that the Company files from time to time with the Securities and Exchange Commission.